Photocure

Less than 1K followers

PHO

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview

Investor consensus

Photocure is a medical technology company. The company specializes in photodynamic technology solutions. The solutions are used to treat diseases that cause bladder cancer and HPV. The main markets are dermatology and oncology, where the products are used by hospitals and research institutes worldwide. The company was founded in 1993 and is headquartered in Oslo, Norway.

Market cap

-

Turnover

-

Revenue

532.58M

EBIT %

-0.14 %

P/E

-

Dividend yield-%

-

Financial calendar

7/5

2026

Interim report Q1'26

25/6

2026

General meeting '26

29/7

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Regulatory press release4/20/2026, 2:31 PM

Photocure ASA: Update on milestone payments from Asieris Pharmaceuticals

Regulatory press release4/20/2026, 2:31 PM

Photocure ASA: Update on milestone payments from Asieris Pharmaceuticals

Regulatory press release4/13/2026, 2:20 PM

PHO: Financial calendar

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release4/13/2026, 6:30 AM

Photocure ASA: Update on Regulatory Classification for OAY Equipment

Regulatory press release4/13/2026, 6:30 AM

Photocure ASA: Update on Regulatory Classification for OAY Equipment

Regulatory press release3/16/2026, 4:00 PM

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Press release3/16/2026, 4:00 PM

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Regulatory press release3/3/2026, 9:35 AM

Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Press release3/3/2026, 9:34 AM

Photocure: Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Press release2/27/2026, 9:17 AM

Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe

Regulatory press release2/18/2026, 6:00 AM

Photocure ASA: Results for the fourth quarter of 2025

Regulatory press release2/18/2026, 6:00 AM

Photocure ASA: Results for the fourth quarter of 2025

Regulatory press release2/11/2026, 4:06 PM

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results

Regulatory press release2/11/2026, 4:06 PM

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results

Regulatory press release1/12/2026, 4:42 PM

New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

Press release1/12/2026, 4:00 PM

Photocure: New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment

Regulatory press release12/29/2025, 1:22 PM

PHO: Financial calendar

Regulatory press release12/8/2025, 7:00 AM

The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

Press release12/8/2025, 7:00 AM

Photocure: The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison

Regulatory press release11/19/2025, 7:00 AM

PHO: New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.